AI Clinical Development
AI clinical development sits where outsourced trial execution, trial-operations software, biosimulation and AI-native data and matching businesses overlap. The verified record shows a crowded, competitive field. Fortrea has adopted Microsoft's AI tooling, ICON runs its delivery on a stack of workflow and document-management software, and Tempus AI competes directly with CROs on data and trial matching. The verified record contains no recent activity, disclosed customer concentration or AI-specific financials, so the case for AI-driven differentiation among the established names is largely unproven. Company-specific governance and disclosure issues at ICON and Fortrea add to the risk. External developments in AI trial matching and U.S. federal programs point to growing activity, but they are not yet confirmed.
Active institutional exposure flipped from a net outflow of $6.6 billion in Q1 2026 to a net inflow of $4.8 billion in Q2 2026. 46.7% of companies in this sub-theme saw increased active positions in Q2 2026.
Overview
AI clinical development covers AI-driven trial design, patient identification and matching, real-world evidence generation and the operational running of trials. The sub-theme has three structural layers. The first is full-service contract research organizations such as IQVIA, ICON, Fortrea and Medpace, with Thermo Fisher's PPD brand as a further competitor for large programs. They run trials on behalf of pharmaceutical and biotechnology sponsors and compete on scale, data assets and delivery. The second is software and modeling vendors. Veeva supplies life-sciences cloud applications, while Certara, Simulations Plus and Schrodinger compete in biosimulation and molecular modeling. The third is data and AI-native participants such as Tempus AI, which offers data and clinical trial matching services and competes against CROs and legacy laboratories. Labcorp is the former parent of Fortrea. The scope excludes CROs without material AI differentiation, so a company's inclusion depends on the strength of its data, software or algorithmic capability rather than on trial-execution capacity alone.
Investment Thesis
Investment thesis details are part of the Pro plan.
Bottleneck Tracker
Bottleneck details are part of the Pro plan.